CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 37,797	$ 39,545
Short-term marketable securities	50,553	62,881
Receivables from collaborative arrangements	18,440	17,474
Receivables from milestones and royalty assets	50,000
Prepaid clinical and development services	73	2,038
Other prepaid and current assets	4,204	11,603
Total current assets	161,067	133,541
Property and equipment, net	7,418	9,068
Operating lease assets	28,354	36,287
Future contingent milestone and royalty assets	144,200	194,200
Restricted cash	836	836
Other assets	12,286	8,067
Total assets	354,161	381,999
Current liabilities:
Accounts payable	2,242	1,524
Accrued personnel-related expenses	7,019	6,443
Accrued clinical and development expenses	1,058	2,246
Accrued general and administrative expenses	2,987	2,900
Operating lease liabilities	10,712	3,923
Income tax payable	5,853
Other accrued liabilities	2,214	1,241
Tenant improvement payable to sublessee		6,490
Total current liabilities	32,085	24,767
Long-term operating lease liabilities	39,108	45,236
Future royalty payment contingency	30,334	27,788
Unrecognized tax benefits	75,199	65,294
Other long-term liabilities	1,890	5,919
Commitments and contingencies (Note 16)
Shareholders' Equity
Preferred shares, $0.00001 par value per share: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 49,471 and 48,091 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively
Additional paid-in capital	1,141,060	1,122,164
Accumulated other comprehensive income (loss)	7	(65)
Accumulated deficit	(965,522)	(909,104)
Total shareholders' equity	175,545	212,995
Total liabilities and shareholders' equity	$ 354,161	$ 381,999